MGNX

1.9601.01%
EM

Edward M. Hurwitz

Independent Director

Mr. Edward M. Hurwitz, J.D., M.B.A., also known as Ed, serves as the Chief Financial Officer at Turmeric Acquisition Corp. Mr. Hurwitz has been an Independent Director at Dyne Therapeutics, Inc. since November 2018. He serves as Executive Chairman at Protego Biopharma, Inc. Mr. Hurwitz served as General Partner at Alta Partners LP. He served as Managing Director of MPM Capital since January 2017 until March 2023. Mr. Hurwitz served as Managing Director at Precision BioVentures, LLC since he founded it in 2013 until December 2016. He served as the Chief Financial Officer and Senior Vice President at Affymetrix from 1997 to 2002. He served as an Interim Chief Executive Officer at Aclara Biosciences Inc. from December 1, 2002 to February 21, 2003. He served as Senior Advisor at Affymetrix Inc. since October 2001. He served as a Biotechnology Research Analyst at Robertson Stephens & Co., L.L.C. from 1994 to 1997 and Smith Barney Inc. (Smith Barney Shearson) from 1992 to 1994. He has professional background in science, business management and law. He has experience as a research analyst, senior executive and lawyer in the biotechnology industry. He has experience investing in life science companies and as a director of public and private biotechnology companies. He practiced commercial law (lawyer) at Cooley Godward L.L.P. from 1990 to 1992. He served as an Equity Analyst at Robertson Stephens, Inc., Research Division and Citigroup Inc., Research Division. He worked at Cooley LLP. Mr. Hurwitz co-founded ViewPoint Therapeutics, Inc. and serves as its Chairman. He serves as Chairman of the board of directors of Rekindle Therapeutics and BioIntervene, Inc. He serves as a Director of ReCode Therapeutics, Protego Biopharma, Inc., FoldRx Pharmaceuticals, Inc. and Avid Radiopharmaceuticals, Inc. He has been Independent Director of MacroGenics, Inc. since October 2004. He had been an Independent Director at Applied Genetic Technologies Corporation since November 2012 to 2022. Mr. Hurwitz served as Director of Alta Partners LP from 2002 to December 2014 and served as a consultant to Alta Partners during 2013 and 2014, Sunesis Pharmaceuticals, Inc. from 2009 to September 18, 2013 and Cara Therapeutics, Inc. from November 28, 2006 to July 16, 2014. He served as a Director of Calistoga Pharmaceuticals, Inc. and Taligen Therapeutics, Inc. He serves as Director of Recode Therapeutics, Inc. He served as an Executive Director of Aclara Biosciences Inc. since October 15, 2002. Mr. Hurwitz has done a J.D. from Berkeley School of Law, University of California, Berkeley, M.B.A. from Berkeley School of Law, University of California, Berkeley in 1990 and a B.A. in Molecular Biology from Cornell University in 1985. Mr. Hurwitz serves as Director of ProRavel Therapeutics, Inc.

Positions